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Abstract
The synthesis and biological analysis of a number of novel congeners of the aminocyclopentitol 
pactamycin is described. Specific attention was paid to the preparation of derivatives at crucial 
synthetic branch points of the parent structure, and biological assays revealed a number of insights 
into the source of pactamycin’s biological activity. Additionally, the encapsulation of pactamycin 
and select derivatives into the PRINT© nanoparticle technology was investigated as a proof-of-
concept, and evidence of bioactivity modulation through nanoparticle delivery is demonstrated. 
This work has provided heretofore unrealized access to a large number of novel compounds for 
further evaluation.
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1. Introduction
Pharmaceutical development through organic synthesis remains a critical feature of the drug 
discovery process.1 Upon identification of an initial hit via high-throughput screening, a 
significant amount of structural modification is often required before a lead candidate can be 
advanced to clinical trials. Natural molecules are often identified as initial hits in these 
screenings; however, later modification of their complex structures toward the preparation 
of useful drug molecules can be hindered by the deficiency of a practical and flexible 
chemical synthesis.2 As a result, the continued advancement of synthetic organic 
methodology is critical for facile and flexible drug discovery and development.
Pactamycin (1, Fig. 1) is an example of a valuable natural target that has yet to reach its full 
medicinal potential, at least in part due to its structural complexity. Isolated in 1961 from a 
fermentation broth of Streptomyces pactum var. pactum by scientists at the former Upjohn 
Chemical Co.,3 pactamycin represents the most complex aminocyclitol antibiotic ever 
discovered. Researchers at Upjohn showed it to be active against Gram-positive and Gram-
negative bacteria as well as against a number of cancer cell lines in vitro.4 More recent 
biological studies have demonstrated pactamycin to have potent antiviral (complete 
inhibition of polio-infected HeLa cells at 10−7 M) and antiprotozoal qualities (P.f. K1: IC50 
= 14.2 nM).5,4b Unfortunately, this promising biological profile is hindered by pactamycin’s 
high cytotoxicity against human eukaryotic cell lines (MRC-5: IC50 = 95 nM).5,4b X-ray 
crystallographic studies have shown that the source of this activity stems from pactamycin’s 
ability to bind to the 30S ribosomal subunit acting as an RNA dinucleotide mimic.6 A 
complex array of H-bonding interactions within the 30S site enables pactamycin to act as a 
universal inhibitor of translocation. Its impressive biology has attracted the attention of a 
multidisciplinary field in hopes of transforming pactamycin into a suitable therapeutic (Fig. 
1).
In addition to 1, a number of naturally-occurring structural congeners have been isolated 
from related Streptomyces bacteria, displaying varied bioactivities. 7-Deoxypactamycin (2) 
and jogyamycin (3) have shown increased antiprotozoal activity relative to 1.7 A third 
natural analog, pactamycate (4), has also been reported.8 Alternatively, biosynthetic 
engineering studies pioneered by Mahmud and co-workers have provided researchers with 
the first series of unnatural structural analogs such as TM-025F (5) and TM-026F (6), which 
display comparable activities to pactamycin against Plasmodium falciparum.8b,9 These data 
have renewed promise for pactamycin analogs in drug development.
Moreover, encapsulation of natural cytotoxic agents into nanoparticles (NPs) has also shown 
improved clinical benefits, the most germane of these being reduction of undesired toxic 
side effects and increased therapeutic delivery to the target of interest. This approach has 
been successfully implemented in the case of doxorubicin (Doxil©),10 paclitaxel 
(Abraxane©)11 and others.12 More recently, Bind Therapeutics13 and Cerulean14 have 
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ongoing clinical trials in NP formulations of cancer therapeutics (docetaxel, irinotecan, and 
camptothecin). DeSimone and co-workers have demonstrated the use of the Particle 
Replication in Non-Wetting Templates (PRINT®) technology to modulate the activity of 
cytotoxic agents such as docetaxel, reducing unwanted side-effects and increasing 
therapeutic activity in vivo.15 To the best of our knowledge, however, the incorporation of 
pactamycin or its congeners into NPs of any type with the goal of bioactivity attenuation has 
not yet been explored.
While an efficient chemical synthesis of 1 might provide the most flexibility in structural 
derivatization, the inherent complexity of the molecule has rendered this a difficult 
undertaking. The heavily-compacted and heteroatom-rich functionality in pactamycin 
presents a number of challenges toward selective structural modification. Additionally, 
while the unique functional groups present in the molecule (salicylate, dimethylurea, aniline) 
offer novel branch points for structural diversification, methods with which to install these 
moieties are underexplored in the literature.16 To these aims, a number of synthetic studies 
have been reported by Isobe, Knapp, Looper, Nishikawa, and our group in the past decade.17 
In 2011, Hanessian and co-workers described the first total synthesis of pactamycin in 32 
steps from L-threonine, enabling previously unrealized access to synthetic congeners.18 
Since this initial publication, Hanessian has demonstrated the efficacy of his route to deliver 
pactamycin derivatives at the C1-dimethylurea and the C3 aniline positions such as 
compounds 7 and 8.19
Our group began work on the total synthesis of 1 in 2009, and this work culminated in 2013 
with a 15-step, asymmetric synthesis from commercially available 2,4-pentanedione (Fig. 
2).20 Critical to our approach was to assemble the molecule in a fashion such that key 
functional groups were installed both in their native form and in a late-stage fashion; we 
surmised that this approach would provide the greatest possible flexibility, facilitating 
investigations of structure-activity relationships at all critical branch points. To this end, we 
envisaged a synthon such as 9 in which exploitation of appropriate functional handles at the 
correct stage would install the requisite functionalities.
A summary of our disclosed synthesis endgame is described in Figure 3, wherein ketone 
intermediate 10 (synthesized in ten steps from 2,4-pentanedione in gram quantities) would 
serve as our first point of derivatization.20 Nucleophilic methylation of 10 proceeded in 
good yield to provide carbinol 11 in 75% yield of a single diastereomer at C5. Sc(OTf)3-
promoted addition of m-acetylaniline installed the substituted C3-aniline necessary for 
elaboration to 1, upon which silyl deprotection afforded tetraol 12. Introduction of the 
remaining salicylate moiety to the C6-hydroxymethylene of 12 was accomplished via 
reaction with the previously reported acyl electrophile 13, which upon hydrogenative 
removal of the Cbz protecting group delivered pactamycin in 15 steps and 1.9% overall 
yield. With this strategy established, we shifted our focus to examining the route’s flexibility 
toward analog preparation.
Herein, we delineate our efforts in the synthesis and biological evaluation of novel 
pactamycin congeners. Additionally, we report the first studies incorporating pactamycin 
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and select derivatives into polymeric NPs, fabricated using the PRINT® technology, with 
the goal of enhancing activity and selectivity while mitigating unwanted toxicities.
2. Results and discussion
2.1. C3-aniline
We first pursued the preparation of pactamycin congeners at the C3-aniline position, 
inspired by a related epoxide-opening strategy by Hanessian and co-workers (Table 1).18,19 
We were encouraged by the aniline flexibility demonstrated by Hanessian in their earlier 
report and hoped that epoxide 11 would participate in related transformations with 
functionally and electronically diverse anilines.
Indeed, we were pleased to find that epoxide 11 reacted readily in the presence of a number 
of substituted anilines in moderate to excellent yields, providing anilines 14a–h. Notably, 
while the installation of m-acetylaniline to 11 necessitated superstoichiometric amounts of 
Sc(OTf)3, all subsequent anilines examined in the reaction proceeded to completion using 50 
mol % Sc(OTf)3. We suspect that this is an outgrowth of both low nucleophilicity and poor 
solubility of the parent m-acetylaniline under the reaction conditions. With the aniline 
tolerance established, we turned our attention to alternative nitrogen nucleophiles. 
Unfortunately, all non-aromatic nitrogen sources (RNH2, R2NH, (−)N3) failed to react with 
11, giving either no reaction or starting material decomposition. Addition products 14a–h 
were carried through the endgame sequence described previously, delivering derivatives 
15a–h (Fig. 4). In the case of addition product 14g, the aryl bromide was reduced during 
hydrogenolysis, delivering α-naphthyl anilide 15g.
2.2. C1-dimethylurea
Hanessian’s approach toward preparation of pactamycin analogs at the C1 dimethylurea 
position substituent relied on the trapping of an in situ generated isocyanate electrophile late 
in the synthesis.18 This tactic proved effective in the preparation of a series of functionalized 
ureas in good yields.19 By contrast, our synthesis of 1 utilized an early-stage N–H insertion 
reaction to install the urea.20 Synthetic diversification from this early intermediate would be 
a significant challenge. Consequently, we envisaged a similar isocyanate formation/trapping 
strategy from carbinol intermediate 11 via the acid-catalyzed elimination of dimethylamine 
(Fig. 6).
After some experimentation, treatment of 11 with NH4Cl in H2O and MeOH resulted in 
complete elimination of dimethylamine and convergence to a single product. However, 1H 
NMR analysis revealed that the intermediate isocyanate had undergone intramolecular ring 
closure with the C2-carbamateto furnish imidazolidinone 17 in 73% yield. Although this 
result rendered our intermolecular isocyanate trapping strategy unfeasible, we postulated 
that this reactivity might be exploited toward analog preparation of the naturally-occurring 
congener pactamycate 4 (Fig. 5).
Selective deprotection of the C7-TBS ether in 16 with oxone furnished the corresponding 
secondary alcohol 18 in 84% yield, which we postulated would serve as a more nucleophilic 
trapping agent for the intermediate isocyanate. Indeed, upon treatment of 18 with NH4Cl in 
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H2O/MeOH, the in situ generated isocyanate underwent trapping by the unprotected C7 
hydroxyl to afford oxazolidinone 19 in 73% yield. Removal of the TBDPS protecting group 
with TBAF provided triol 20, which upon Cbz deprotection, afforded De-6-MSA 
pactamycate 21, which has been previously characterized.18b This result confirmed that the 
intermediate isocyanate generated from 18 had indeed been engaged by the C7 hydroxyl 
(and not the C2 carbamate). With this route established, we resolved to prepare a subset of 
varied C3 pactamycate structures. Beginning with anilides 14b, 14c, and 14e already in hand 
from the C3 derivatization studies, TBS deprotection followed by oxazolidinone formation 
gave the corresponding diols, which upon desilylation, acylation and hydrogenolysis, 
provided pactamycate derivatives 22a–c.
2.3. C5-tertiary alcohol
We next began examining reactivity of the ketone in 10 with the goal of diversification at 
C5 (Table 2). To this end, we were pleased to find this ketone reacted readily with 
ethyl, nhexyl, and vinyl magnesium bromide to give the corresponding carbinols in good 
yields. Unfortunately, when larger alkyl (entries 4, 5 and 8) and aryl nucleophiles (entries 6 
and 7) were examined, we observed only un-productive side reactions21 or complete starting 
material recovery. With this limitation established, we speculated that hydride might also be 
a suitable nucleophile. In the event, treatment of 10 with NaBH4 in MeOH at −45 °C 
provided alcohol 23c in good yield with analogous stereofidelity to that observed in the 
addition of carbon nucleophiles.
With addition products 23a–c in hand, we proceeded in the synthesis to complete C5 analog 
preparation (Fig. 7). We were surprised to find, however, that subjection of these 
intermediates to the optimized conditions for C3 m-acetylaniline installation gave only 
significant amounts of recovered starting material. Increasing the loading of Sc(OTf)3 or the 
reaction time/temperature had seemingly no effect. It seems reasonable that this addition is 
sluggish either due to poor coordination of the Lewis acid or by an unfavorable substrate 
conformation for addition relative to the parent C5-methyl compound (11). In order to 
circumvent this issue, we turned to the strategy of Hannesian and coworkers wherein the 
required C3 m-acetylaniline was incorporated via an 2-(prop-1-en-2-yl)aniline surrogate.18 
The acetophenone was later revealed via oxidation. In our system, this strategy also proved 
effective, providing 2-(prop-1-en-2-yl)aniline anilines 24a–c in good yields. Johnson–
Lemieux oxidation of the resulting alkenes provided the desired m-acetylanilines 25a–c in 
good yields over the three-step sequence. Completion of the remaining synthetic sequence 
provided C5 pactamycin derivatives 26a–c.
2.4. C6,C7-hydroxyl
The final point of diversification centered on manipulation of the salicylate-bearing C6 ester 
in 1 (Table 3). Gratifyingly, efficient monoacylation of tetraol 12 was accomplished with a 
variety of aliphatic and aromatic acyl electrophiles in good yields (entries 1–5). The 
resulting monoesters were subjected to the previously employed conditions for Cbz 
deprotection, providing derivatives 27b–e. However, in the case of the differentiated 
methoxyphenol 27a (entry 1), only decomposition was observed upon hydrogenolysis.
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Cognizant of the documented bioactivity difference across multiple cell lines observed 
between 1 and its 7-deoxy congener (2),7 reduction of the C7-hydroxyl to its corresponding 
methylene was also probed. Unfortunately, all conditions explored (from a number of 
different intermediates in our route) failed to deliver the desired C7-methylene. As an 
alternative strategy, we envisaged masking of the C7 hydroxyl via its ester might serve the 
same purpose (i.e., removal of the H-bonding interaction at C7).6 To this end, C6–C7 bis-
acylated derivatives (entries 6–8) were synthesized with varying degrees of steric 
encumbrance. Cbz hydrogenolysis provided the diesters 27f–h.
3. Results and discussion
3.1. Biological evaluation
Having prepared a library of novel compounds, we set out to examine their varied biological 
profiles. Specifically, compounds were tested against breast, ovarian, and lung carcinoma 
cell lines. Additionally, the human embryonic cell line for which pactamycin’s toxicity has 
been established (MRC-5) was assayed for comparison.5,4b The results for all derivatives are 
summarized in Table 4. As anticipated, pactamycin (entry 1) displayed exceptional potency, 
showing nanomolar inhibition against all three carcinoma cell lines. For comparison, the 
penultimate intermediate in our synthesis of pactamycin (28) bearing Cbz protection at the 
C2-aminomethine (entry 2) showed a dramatic decrease in activity relative to 1. In order to 
better understand the effect of chirality on the parent pactamycin structure, ent-pactamycin 
(ent-(1)) (entry 3) was synthesized in high enantiomeric purity via a slight modification of 
the previously published route (see Supporting information) and assayed in our study. As 
illustrated in Table 4, ent-(1) showed a threefold order of magnitude decrease in bioactivity, 
illustrating the impact of the natural enantiomer of 1 to effective cell-growth inhibition.
Generally, all C3-aniline derivatives (entries 4–11) showed a marginal to significant 
decrease in activity relative to 1 across all cell lines, although 15b (entry 5) showed 
comparable activity against A549 (EC50 = 141 nM) with a marginal decrease in MRC5 
activity. With regard to the pactamycate series of analogs, De-6-MSA pactamycate 21 (entry 
12) showed only minor cell-growth inhibition. This was not an altogether unexpected result, 
however, as biological assays of 21 conducted by Hanessian and co-workers also showed 
little promising activity.19,6c Altering the C3 aniline position of the pactamycate parent 
structure (entries 13–15) resulted in complete loss of biological activity. These results, in 
combination with those of the pactamycin C3 analogs, speak to the importance of the m-
acetyl functionality in 1 to its bioactivity.22
The results of compounds bearing diversity at C5 are shown in entries 16–19. In 
combination with the C5 derivatives previously described (vide supra), an additional 
derivative 29 (entry 19) was prepared bearing alternate functionality at the C3 aniline for 
comparison (see Supporting information). Extending the length of the carbon chain at C5 
(entries 16 and 17) had significantly deleterious effects to bioactivity as a complete loss of 
carcinoma activity was observed, leaving only low inhibition of MRC-5. However, 
removing alkyl functionality altogether at C5 (entries 18 and 19) had the opposite effect, as 
these C5 protio analogs displayed the greatest activity across all cell lines of any compound 
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tested in our study (including pactamycin). We speculate that these results are primarily a 
function of adjusting the lipophilicity of the structure relative to 1.23
The results of our diversification of the C6 hydroxymethylene (entries 22–25) are in 
agreement with Hanessian’s earlier findings.19,6c Namely, no significant gain (or loss) of 
biological activity was observed when the salicylate ester was altered relative to the parent 
pactamycin structure. These results further support the hypothesis that the C6 ester side 
chain has a limited role in the key binding event of 1 in the 30S ribosome.19,6c The three 
prepared C6,C7 bis-acylated derivatives (entries 24–26) showed a linear decrease in activity 
with steric encumbrance of the ester group. These results suggest that the C7 hydroxyl in 1 
plays a larger role in the bioactivity of the structure than the C6 hydroxymethylene.
Upon collection of these initial data, derivatives 15f, 26c, 27f, 27c, and ent-(1) were 
identified as the most promising compounds and were assayed via the NCI 60 human tumor 
cell line screen. Upon initial one-dose screening, all five compounds were found to have 
sufficient activity to merit the subsequent five-dose assay. These derivatives were evaluated 
to determine GI50 (50% growth inhibition) values. The results of these assays are 
summarized in Table 5. Additionally, the previously documented cell data for 1 is shown for 
comparison.
As expected based on our initial screen, ent-(1) showed multiple orders of magnitude loss in 
activity across the entire assay. By contrast, compound 26c bearing a secondary hydroxyl at 
C5 demonstrated exceptional activity, showing nM inhibition throughout the screen and 
outperforming pactamycin in multiple cell lines. Derivatives 27c (modified salicylate ester) 
and 27f (C6, C7 diace-toxypactamycin) also demonstrated general nM activity in the assay. 
The final derivative 15f bearing a fluorenyl aniline at C3 showed a general decrease in 
biological activity relative to 1 by factors of 10–100.
3.2. Nanoparticle fabrication-biological evaluation
With these studies completed, we set out to examine the efficacy of pactamycin and select 
analogs to activity modulation via nanoparticle encapsulation. Polymeric PRINT® 
nanoparticles were fabricated by encapsulating compounds 1, 15e, and 26c, in poly(D,L-
lactide) using previously described methods.15b,24 Compounds 15e and 26c were selected on 
the basis of observing the effect of nanoformulation on derivatives both more and less 
bioactive than 1. PRINT NPs containing 1 and derivatives 15e and 26c all showed similar 
hydrodynamic radii and PDI as determined by dynamic light scattering (DLS).25 Scanning 
electron microscopy (SEM) analysis confirmed uniform particle size and shape regardless of 
compound identity, and drug loading of each sample was found to be ~10% as determined 
by HPLC.26 NP-encapsulated compounds NP-1, NP-15e, and NP-26c, were then examined 
in our assay, and the results are given in Table 6 where the baseline toxicity values for each 
compound are restated for comparison.
In vitro cytotoxicity analysis of the derivative NP formulations showed bimodal effects on 
therapeutic activity. In the A549 assay, nanoparticle delivery increased the cytotoxicity of 
the therapeutic cargo. NP-1 demonstrated an EC50 threefold more potent than pactamycin 
itself (52–160 nm, respectively). NP-26c showed a near fivefold increase in potency when 
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compared to the unadulterated small molecule (6.5–32 nM, respectively). Even compounds 
15e, a less active drug in comparison to 1, showing a nominal reduction in EC50 value for 
the A549 cell line. Of significant interest was the increase in selectivity observed for 26c, 
wherein the EC50 for A549 decreased while the EC50 for MDA-MB-231 and MRC5 
increased.
4. Conclusions
In summary, we have demonstrated the efficacy of our synthetic approach to efficient and 
modular preparation of a number of varied analogs of the complex aminocyclitol 
pactamycin. These results have provided additional insight into the roles that each functional 
group plays in providing the observed activity of the parent structure. Additionally, we have 
established a heretofore undocumented proof-of-concept for the modulation of the 
pactamycin structure via the use of the PRINT® nanoparticle delivery vehicle. A wider 
range of cell-based assays and the further examination of pactamycin derivatives using the 
PRINT technology is planned and will be reported in due course.
Supplementary Material
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Structures of pactamycin (1) and natural, synthetic, and biosynthetic congeners.
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Synthon analysis of 1 showing key branch points for structural derivatization.
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Pactamycin: endgame strategy and synthesis completion.
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Synthesis of C3 aniline pactamycin derivatives. aHydrogenation of the of bromide 
functionality was observed.
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Preparation of de-6-MSA pactamycate and pactamycate analogs. Conditions: (a) oxone, 
CH3CN/H2O (9:1), rt; (b) NH4Cl, MeOH/H2O (8:1), 85 °C; (c) TBAF, THF, 0 °C; (d) H2 (1 
atm), Pd(OH)2/C (0.5 mass equiv), MeOH, rt; (e) aniline (10 equiv), Sc(OTf)3 (50 mol %), 
PhMe, 50 °C; (f) K2CO3,13, DMA, rt.
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Failed isocyanate formation/trapping strategy from 11.
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Preparation of C5 pactamycin analogs. Conditions: (a) m-propenylaniline (10 equiv), 
Sc(OTf)3 (50 mol %), C7H8, 50 °C; (b) OsO4 (10 mol %), NMO (5 equiv), THF/
acetone/H2O (5:5:1), 0 °C–rt; (c) NalO4 (3.5 equiv), THF/H2O (1:1), rt; (d) TBAF, THF, 
0°C; (e) K2CO3, 13, DMA, rt; (f) H2 (1 atm), Pd(OH)2/C (0.5 mass equiv), MeOH, rt.
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Table 1
Addition of substituted anilines and other nitrogen nucleophiles to epoxide 11










10 BnNH2 – –c




TBS deprotection was observed as the sole product.
c
No reaction was observed.
d
Conditions: NaN3 (1.1 equiv), oxone (0.5 equiv), CH3CN/H2O (9:1), rt; only TBS deprotection was observed in this reaction.
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Table 2
Addition of nucleophiles to ketone 10a
Entry R Product % Yieldb
1 Et 23a 75






8 PhCH2 – –e




Product could not be elaborated further.
c
No reaction was observed.
d




Conditions: NaBH4, MeOH, −45 °C.
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Table 6







1 160 124 nM 53 nM
NP-1 52 117 nM 52 nM
15e 884 3.3 μM 2.3 μM
NP-15e 693 5.5 μM 1.8 μM
26c 32 50 nM 6.5 nM
NP-26c 6.5 724 nM 18 nM
a
Assays were carried out as triplicates
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